Curative effect and safety of decitabine combined with HAG for patients with myelodysplastic syndromes
10.7501/j.issn.1674-6376.2017.08.024
- VernacularTitle:地西他滨联合HAG方案治疗骨髓增生异常综合征的临床疗效及其安全性评价
- Author:
Ying YANG
1
;
mei Hong GUAN
;
li Wan CHEN
;
Shu WANG
;
Bing LIU
Author Information
1. 南阳市第二人民医院血液科
- Keywords:
decitabine;
myelodysplastic syndromes;
curative effect;
adverse reaction
- From:
Drug Evaluation Research
2017;40(8):1149-1152
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the curative effect and safety of decitabine combined with HAG for patients with myelodysplastic syndromes.Methods Fifty-six patients with myelodysplastic syndromes in Nanyang Second General Hospital from August 2014 to August 2016 were divided randomly into control group (n =26,accepted HAG chemotherapy) and study group (n =30,adopted decitabine combined with HAG) to compare the clinical curative and the incidence of adverse reactions between two groups.Results After a course of treatment,the total remission of control group was 26.9％,and study group was 30％,and difference was no significance between two groups.After two courses of treatment,the total remission of study group (83.3％) was higher significantly than those of control group (57.7％).The case of adverse reactions of study group (25 cases) was lower than control group significantly (P ＜ 0.05).Conclusions Decitabine assisted HAG chemotherapy could improve the clinical curative effect remarkably for patients myelodysplastic syndromes,which deserved popularization in clinic duo to the decreasing incidence of adverse reactions and the well quality of life.
